Patent details
EP3682884 Title: CRYSTALLINE FORMS OF DAPRODUSTAT (GSK1278863), A PERORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) FOR TREATING ANEMIA, AND THEIR PREPARATION METHODS
Basic Information
- Publication number:
- EP3682884
- PCT Application Number:
- CN2018078766
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP188573752
- PCT Publication Number:
- WO2019052133
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- CRYSTALLINE FORMS OF DAPRODUSTAT (GSK1278863), A PERORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) FOR TREATING ANEMIA, AND THEIR PREPARATION METHODS
- French Title of Invention:
- FORMES CRYSTALLINES DE DAPRODUSTAT (GSK1278863), UN INHIBITEUR DE L'ENZYME PROLYL HYDROXYLASE DU FACTEUR INDUCTIBLE PAR HYPOXIE PERORAL (HIF-PHI) POUR LE TRAITEMENT DE L'ANÉMIE, ET LEURS PROCÉDÉS DE PRÉPARATION
- German Title of Invention:
- KRYSTALLINE FORMEN VON DAPRODUSTAT (GSK1278863), EIN PERORALER HYPOXIE-INDUZIERBAREN FAKTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) ZUR BEHANDLUNG VON ANÄMIE, UND IHRE HERSTELLUNGSVERFAHREN
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 07/05/2024
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 21/05/2024
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 24/04/2024
- Unitary Effect Registration Date:
- 21/05/2024
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 13/03/2018
- Grant date:
- 24/04/2024
- EP Publication Date:
- 22/07/2020
- PCT Publication Date:
- 21/03/2019
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 24/04/2024
- EP B1 Publication Date:
- 24/04/2024
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 13/03/2038
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 17/04/2024
- Name:
- GlaxoSmithKline Intellectual Property (No. 2) Limited
- Address:
- GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom (GB)
Inventor
1
- Name:
- CHEN, Minhua
- Address:
- China (CN)
2
- Name:
- ZHANG, Xiaoyu
- Address:
- China (CN)
3
- Name:
- WANG, Jinqiu
- Address:
- China (CN)
4
- Name:
- ZHANG, Yanfeng
- Address:
- China (CN)
Priority
- Priority Number:
- 201710835313
- Priority Date:
- 15/09/2017
- Priority Country:
- China (CN)
Classification
- IPC classification:
- C07D 239/62; A61K 31/515; A61P 7/06;
Publication
European Patent Bulletin
1
- Issue number:
- 202417
- Publication date:
- 24/04/2024
- Description:
- Grant (B1)
2
- Issue number:
- 202424
- Publication date:
- 12/06/2024
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202425
- Publication date:
- 19/06/2024
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|